MNPR Monopar Therapeutics

Monopar to Present at Roth Inaugural Healthcare Opportunities Conference

Monopar to Present at Roth Inaugural Healthcare Opportunities Conference

WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the Roth Inaugural Healthcare Opportunities Conference.

Presentation Details:

Date: October 6, 2022

Time: 12:00 p.m. (ET)

Location: The Yale Club, New York City, New York



About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: .

CONTACT:  

Monopar Therapeutics Inc.

Investor Relations  

Kim R. Tsuchimoto  

Chief Financial Officer  

Follow Monopar on social media for updates: 

Twitter:   LinkedIn:

 



EN
28/09/2022

Underlying

MNPRMonopar Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Monopar Therapeutics

 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russ...

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes WILMETTE, Ill., June 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the close of U.S. equity markets on June 27, 2025. The inclusion follows the initial announcement on Friday, May...

June 3, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Therapeutics Reports First Quarter 2025 Financial Results and ...

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On May 7, 2025, Monopar presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline) at the European Assoc...

May 13, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, one of the most prominent global conferences in liver disease. Monopar’s late-breaker p...

May 7, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation...

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver (“EASL”) International Liver Congre...

April 29, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results an...

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced fourth quarter and full-year 2024 financial results and summarized recent developments. “2024 was a productive year for Monopar, with the in-licensing of ALXN1840, the initiation of two first-in-human radiopharma Phase 1 clinical trials, and the strengthening of our ...

March 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch